Hims & Hers Health (NYSE:HIMS) Trading Up 0.4%

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price was up 0.4% on Monday . The company traded as high as $22.41 and last traded at $22.23. Approximately 1,623,111 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 7,136,217 shares. The stock had previously closed at $22.15.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several analyst reports. Guggenheim upped their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, February 27th. Piper Sandler increased their price objective on shares of Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a report on Tuesday, May 7th. Truist Financial raised their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Bank of America raised their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Thursday, June 13th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $15.00 target price (down from $17.00) on shares of Hims & Hers Health in a report on Tuesday, April 16th. Seven research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.43.

Hims & Hers Health Stock Performance

The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of -2,196.00 and a beta of 1.08. The company has a 50-day moving average price of $17.08 and a 200-day moving average price of $13.30.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. The company had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.05) EPS. As a group, sell-side analysts anticipate that Hims & Hers Health, Inc. will post 0.19 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Christiane Pendarvis sold 4,000 shares of Hims & Hers Health stock in a transaction on Monday, May 13th. The stock was sold at an average price of $12.33, for a total value of $49,320.00. Following the sale, the director now directly owns 11,210 shares of the company’s stock, valued at approximately $138,219.30. The disclosure for this sale can be found here. In the last three months, insiders sold 962,791 shares of company stock worth $16,930,725. 17.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Belpointe Asset Management LLC grew its holdings in shares of Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after purchasing an additional 1,205 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Hims & Hers Health by 5.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after buying an additional 1,561 shares in the last quarter. Swiss National Bank grew its stake in Hims & Hers Health by 0.7% in the 1st quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares during the period. ProShare Advisors LLC grew its stake in Hims & Hers Health by 10.0% in the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock valued at $344,000 after purchasing an additional 2,023 shares during the period. Finally, Principal Financial Group Inc. grew its stake in Hims & Hers Health by 17.9% in the 1st quarter. Principal Financial Group Inc. now owns 16,655 shares of the company’s stock valued at $258,000 after purchasing an additional 2,525 shares during the period. Institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.